Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional TUSCAN Lymphoma Network)—Authors' reply to Morris and colleagues-Reference-Cited by-同舟云学术

Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional TUSCAN Lymphoma Network)—Authors' reply to Morris and colleagues

Published:2022-07-28 Issue:5 Volume:109 Page:595-596
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Cencini Emanuele¹^ORCID,Fabbri Alberto¹

Affiliation:

1. Unit of Hematology Azienda Ospedaliera Universitaria Senese and University of Siena Siena Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13831

Reference10 articles.

1. Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma

2. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi ( FIL )

3. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

4. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

5. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term efficacy in patients with relapsed/refractory diffuse large B‐cell lymphoma achieving a complete response with pixantrone;European Journal of Haematology;2023-05-10